LY 801221 (Eli Lilly) meets end point in NSCLC trial
SQUIRE, a newly-completed Phase III study of LY 801221 (necitumumab), from Eli Lilly, met its primary endpoint in patients with stage IV metastatic squamous Non-Small Cell Lung Cancer (NSCLC). Patients experienced increased overall survival when administered necitumumab in combination with gemcitabine and cisplatin as a first-line treatment, as compared to chemotherapy alone.
The most common adverse events occurring more frequently in patients on the necitumumab arm were rash and hypomagnesemia. Serious, but less frequent, adverse events occurring more often on the necitumumab arm included thromboembolism. Eli Lilly plans to present results from this study at a scientific meeting in 2014, and currently anticipates submitting to regulatory authorities before the end of 2014.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins